Global Raynaudís Phenomenon Management Market
Global Raynaudís Phenomenon Management Market

Raynaudís Phenomenon Management Comprehensive Study by Test (Antinuclear Antibodies Test, Erythrocyte Sedimentation Rate Test, C-reactive Protein Test, Others), Treatment Type (Medication (Calcium Channel Blockers, Vasodilator), Surgeries and Medical Procedures (Nerve Surgery, Chemical Injection, Others)), End-Use (Hospital, Clinics, Others)

Raynaudís Phenomenon Management Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jun 2021 Edition 200 Pages 217 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Raynaudís Phenomenon Management Market?

Raynaudís phenomenon is caused by episodic vasospasm and ischemia of the extremities in response to cold or emotional stimuli, which result in a characteristic triphasic color change in extremities usually fingers or toes from white to blue, to red. Raynaudís phenomenon is in direct reaction to stimuli, or secondary to a primary condition. In 10-20% of cases it may be the first presentation of, or may precede the onset of, a connective tissue disease (such as scleroderma or mixed connective tissue disease) so that underlying causes must be ruled out. Raynaudís phenomenon is generated by a change in temperature rather than simply exposure to cold. The average age of onset is lower in women as compared to men, and prevalence is higher in colder climates. The primary reasons for getting Raynauds disease are the extremely cold temperature, stress, and hypertension and the chances of this disease might increase because of diseases like lupus, rheumatoid arthritis, and Sjogren's syndrome. The Raynauds disease affects up to 20% of the adult population around the world most common in females than in men, the primary type of this disease usually begins at the age of 20s or 30s and the second type might develop at any age depending on the cause.

The market study is being classified and major geographies with country level break-up.

Sanofi S.A (France), GlaxoSmithKline (United Kingdom), Mylan Inc. (United States), Apricus Biosciences Inc. (United States), Harbin Clinic (United States), Pacira (Skyepharma) (United States), Biomag Medical s.r.o. (Czech Republic), Bayer AG (Germany), Healthy Life Pharma Private Limited (India), Duchefa Farma B.V (Netherlands), Pfizer (United States), Teva Pharmaceutical Industries Ltd. (Israel), Apricus Biosciences, Inc. (United States) and Covis Pharmaceuticals, Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Sandoz International GmbH (Germany) and Unichempharma (India).

Research Analyst at AMA predicts that European Players will contribute to the maximum growth of Global Raynaudís Phenomenon Management market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Raynaudís Phenomenon Management market by Type, Application and Region.

On the basis of geography, the market of Raynaudís Phenomenon Management has been segmented into . Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Growing Prevalence of Raynauds Phenomenon in People Living in Cold Regions
  • Increase in the Risk of Raynauds Disease Due to the Disease Lupus, Rheumatoid Arthritis and Sjogren's Syndrome

Market Trend
  • Treatment for Raynauds Disease like Changes in Lifestyle is Growing Due to the Prevailing Causes like Stress and Hypertension
  • Continuous Research and Development in the Raynauds Disease Treatment

Restraints
  • Health Side Effects Associated with Raynauds Disease Treatment to Pregnant Ladies
  • Regulatory Compliance with Raynauds Disease Treatment

Opportunities
  • Various Health Awareness Programs about the Raynaud's Disease Will Drive the Market for Treatments
  • Rising Severity and Painful Symptoms Associated with Raynaud's Disease is Increasing Demand for Raynauds Disease Treatment

Challenges
  • High-Cost Maintenance and Treatment Equipment Set up Involved in the Raynauds Disease Might Hamper the Market
  • Lack of Awareness about the Raynauds Disease Might be the Hindrance for the Market



A number of pharmacologic treatments have been studied, but none provide a cure and none has been approved for this indication in the United States. In an international study of patients with self-reported Raynaud phenomenon, 82% reported that at least one currently used medication was tolerated, but only 16% reported that at least one current medication was effective. For the primary Raynaud phenomenon, the first line of therapy consists of lifestyle measures, such as avoidance of precipitating factors and the use of gloves. If these prove inadequate, the patient may be considered for calcium channel blocker treatment; nifedipine is the usual choice. If lifestyle changes don't control Raynaud's, you may need medicines or surgery. Medicines are used to improve blood flow to the fingers and toes. Examples of medicines used to treat Raynaud's include calcium channel blockers, alpha-blockers, prescription skin creams, and ACE inhibitors (used less often).

Key Target Audience
Raynauds Disease Treatment Providers, Raynauds Disease Treatment Medication and Equipment Manufacturers, Research and Development Institutes, Health Care Industry, End-User and Others

Frequently Asked Questions (FAQ):

1. Which factors would majorly drive the Raynaudís Phenomenon Management Market?
"Growing Prevalence of Raynauds Phenomenon in People Living in Cold Regions " is seen as one of major growth factors of Raynaudís Phenomenon Management Market in years to come.

2. Can we have customized study for Raynaudís Phenomenon Management Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

3. Which region will lead the Global Raynaudís Phenomenon Management Market?
will lead the Raynaudís Phenomenon Management Market.
Report Objectives / Segmentation Covered
By Test
  • Antinuclear Antibodies Test
  • Erythrocyte Sedimentation Rate Test
  • C-reactive Protein Test
  • Others

By Treatment Type
  • Medication (Calcium Channel Blockers, Vasodilator)
  • Surgeries and Medical Procedures (Nerve Surgery, Chemical Injection, Others)

By End-Use
  • Hospital
  • Clinics
  • Others

By Regions
    • 1. Market Overview
      • 1.1. Introduction
      • 1.2. Scope/Objective of the Study
        • 1.2.1. Research Objective
    • 2. Executive Summary
      • 2.1. Introduction
    • 3. Market Dynamics
      • 3.1. Introduction
      • 3.2. Market Drivers
        • 3.2.1. Growing Prevalence of Raynauds Phenomenon in People Living in Cold Regions
        • 3.2.2. Increase in the Risk of Raynauds Disease Due to the Disease Lupus, Rheumatoid Arthritis and Sjogren's Syndrome
      • 3.3. Market Challenges
        • 3.3.1. High-Cost Maintenance and Treatment Equipment Set up Involved in the Raynauds Disease Might Hamper the Market
        • 3.3.2. Lack of Awareness about the Raynauds Disease Might be the Hindrance for the Market
      • 3.4. Market Trends
        • 3.4.1. Treatment for Raynauds Disease like Changes in Lifestyle is Growing Due to the Prevailing Causes like Stress and Hypertension
        • 3.4.2. Continuous Research and Development in the Raynauds Disease Treatment
    • 4. Market Factor Analysis
      • 4.1. Porters Five Forces
      • 4.2. Supply/Value Chain
      • 4.3. PESTEL analysis
      • 4.4. Market Entropy
      • 4.5. Patent/Trademark Analysis
    • 5. Global Raynaudís Phenomenon Management, by Test, Treatment Type and End-Use (value) (2015-2020)
      • 5.1. Introduction
      • 5.2. Global Raynaudís Phenomenon Management (Value)
        • 5.2.1. Global Raynaudís Phenomenon Management by: Test (Value)
          • 5.2.1.1. Antinuclear Antibodies Test
          • 5.2.1.2. Erythrocyte Sedimentation Rate Test
          • 5.2.1.3. C-reactive Protein Test
          • 5.2.1.4. Others
        • 5.2.2. Global Raynaudís Phenomenon Management by: Treatment Type (Value)
          • 5.2.2.1. Medication (Calcium Channel Blockers, Vasodilator)
          • 5.2.2.2. Surgeries and Medical Procedures (Nerve Surgery, Chemical Injection, Others)
        • 5.2.3. Global Raynaudís Phenomenon Management by: End-Use (Value)
          • 5.2.3.1. Hospital
          • 5.2.3.2. Clinics
          • 5.2.3.3. Others
    • 6. Raynaudís Phenomenon Management: Manufacturers/Players Analysis
      • 6.1. Competitive Landscape
        • 6.1.1. Market Share Analysis
          • 6.1.1.1. Top 3
          • 6.1.1.2. Top 5
      • 6.2. Peer Group Analysis (2020)
      • 6.3. BCG Matrix
      • 6.4. Company Profile
        • 6.4.1. Sanofi S.A (France)
          • 6.4.1.1. Business Overview
          • 6.4.1.2. Products/Services Offerings
          • 6.4.1.3. Financial Analysis
          • 6.4.1.4. SWOT Analysis
        • 6.4.2. GlaxoSmithKline (United Kingdom)
          • 6.4.2.1. Business Overview
          • 6.4.2.2. Products/Services Offerings
          • 6.4.2.3. Financial Analysis
          • 6.4.2.4. SWOT Analysis
        • 6.4.3. Mylan Inc. (United States)
          • 6.4.3.1. Business Overview
          • 6.4.3.2. Products/Services Offerings
          • 6.4.3.3. Financial Analysis
          • 6.4.3.4. SWOT Analysis
        • 6.4.4. Apricus Biosciences Inc. (United States)
          • 6.4.4.1. Business Overview
          • 6.4.4.2. Products/Services Offerings
          • 6.4.4.3. Financial Analysis
          • 6.4.4.4. SWOT Analysis
        • 6.4.5. Harbin Clinic (United States)
          • 6.4.5.1. Business Overview
          • 6.4.5.2. Products/Services Offerings
          • 6.4.5.3. Financial Analysis
          • 6.4.5.4. SWOT Analysis
        • 6.4.6. Pacira (Skyepharma) (United States)
          • 6.4.6.1. Business Overview
          • 6.4.6.2. Products/Services Offerings
          • 6.4.6.3. Financial Analysis
          • 6.4.6.4. SWOT Analysis
        • 6.4.7. Biomag Medical s.r.o. (Czech Republic)
          • 6.4.7.1. Business Overview
          • 6.4.7.2. Products/Services Offerings
          • 6.4.7.3. Financial Analysis
          • 6.4.7.4. SWOT Analysis
        • 6.4.8. Bayer AG (Germany)
          • 6.4.8.1. Business Overview
          • 6.4.8.2. Products/Services Offerings
          • 6.4.8.3. Financial Analysis
          • 6.4.8.4. SWOT Analysis
        • 6.4.9. Healthy Life Pharma Private Limited (India)
          • 6.4.9.1. Business Overview
          • 6.4.9.2. Products/Services Offerings
          • 6.4.9.3. Financial Analysis
          • 6.4.9.4. SWOT Analysis
        • 6.4.10. Duchefa Farma B.V (Netherlands)
          • 6.4.10.1. Business Overview
          • 6.4.10.2. Products/Services Offerings
          • 6.4.10.3. Financial Analysis
          • 6.4.10.4. SWOT Analysis
        • 6.4.11. Pfizer (United States)
          • 6.4.11.1. Business Overview
          • 6.4.11.2. Products/Services Offerings
          • 6.4.11.3. Financial Analysis
          • 6.4.11.4. SWOT Analysis
        • 6.4.12. Teva Pharmaceutical Industries Ltd. (Israel)
          • 6.4.12.1. Business Overview
          • 6.4.12.2. Products/Services Offerings
          • 6.4.12.3. Financial Analysis
          • 6.4.12.4. SWOT Analysis
        • 6.4.13. Apricus Biosciences, Inc. (United States)
          • 6.4.13.1. Business Overview
          • 6.4.13.2. Products/Services Offerings
          • 6.4.13.3. Financial Analysis
          • 6.4.13.4. SWOT Analysis
        • 6.4.14. Covis Pharmaceuticals, Inc. (United States)
          • 6.4.14.1. Business Overview
          • 6.4.14.2. Products/Services Offerings
          • 6.4.14.3. Financial Analysis
          • 6.4.14.4. SWOT Analysis
    • 7. Global Raynaudís Phenomenon Management Sale, by Test, Treatment Type and End-Use (value) (2021-2026)
      • 7.1. Introduction
      • 7.2. Global Raynaudís Phenomenon Management (Value)
        • 7.2.1. Global Raynaudís Phenomenon Management by: Test (Value)
          • 7.2.1.1. Antinuclear Antibodies Test
          • 7.2.1.2. Erythrocyte Sedimentation Rate Test
          • 7.2.1.3. C-reactive Protein Test
          • 7.2.1.4. Others
        • 7.2.2. Global Raynaudís Phenomenon Management by: Treatment Type (Value)
          • 7.2.2.1. Medication (Calcium Channel Blockers, Vasodilator)
          • 7.2.2.2. Surgeries and Medical Procedures (Nerve Surgery, Chemical Injection, Others)
        • 7.2.3. Global Raynaudís Phenomenon Management by: End-Use (Value)
          • 7.2.3.1. Hospital
          • 7.2.3.2. Clinics
          • 7.2.3.3. Others
    • 8. Appendix
      • 8.1. Acronyms
    • 9. Methodology and Data Source
      • 9.1. Methodology/Research Approach
        • 9.1.1. Research Programs/Design
        • 9.1.2. Market Size Estimation
        • 9.1.3. Market Breakdown and Data Triangulation
      • 9.2. Data Source
        • 9.2.1. Secondary Sources
        • 9.2.2. Primary Sources
      • 9.3. Disclaimer
    List of Tables
    • Table 1. Raynaudís Phenomenon Management: by Test(USD Million)
    • Table 2. Raynaudís Phenomenon Management: by Treatment Type(USD Million)
    • Table 3. Raynaudís Phenomenon Management: by End-Use(USD Million)
    • Table 4. Company Basic Information, Sales Area and Its Competitors
    • Table 5. Company Basic Information, Sales Area and Its Competitors
    • Table 6. Company Basic Information, Sales Area and Its Competitors
    • Table 7. Company Basic Information, Sales Area and Its Competitors
    • Table 8. Company Basic Information, Sales Area and Its Competitors
    • Table 9. Company Basic Information, Sales Area and Its Competitors
    • Table 10. Company Basic Information, Sales Area and Its Competitors
    • Table 11. Company Basic Information, Sales Area and Its Competitors
    • Table 12. Company Basic Information, Sales Area and Its Competitors
    • Table 13. Company Basic Information, Sales Area and Its Competitors
    • Table 14. Company Basic Information, Sales Area and Its Competitors
    • Table 15. Company Basic Information, Sales Area and Its Competitors
    • Table 16. Company Basic Information, Sales Area and Its Competitors
    • Table 17. Company Basic Information, Sales Area and Its Competitors
    • Table 18. Raynaudís Phenomenon Management: by Test(USD Million)
    • Table 19. Raynaudís Phenomenon Management: by Treatment Type(USD Million)
    • Table 20. Raynaudís Phenomenon Management: by End-Use(USD Million)
    • Table 21. Research Programs/Design for This Report
    • Table 22. Key Data Information from Secondary Sources
    • Table 23. Key Data Information from Primary Sources
    List of Figures
    • Figure 1. Porters Five Forces
    • Figure 2. Supply/Value Chain
    • Figure 3. PESTEL analysis
    • Figure 4. Global Raynaudís Phenomenon Management: by Test USD Million (2015-2020)
    • Figure 5. Global Raynaudís Phenomenon Management: by Treatment Type USD Million (2015-2020)
    • Figure 6. Global Raynaudís Phenomenon Management: by End-Use USD Million (2015-2020)
    • Figure 7. Global Raynaudís Phenomenon Management share by Players 2020 (%)
    • Figure 8. Global Raynaudís Phenomenon Management share by Players (Top 3) 2020(%)
    • Figure 9. Global Raynaudís Phenomenon Management share by Players (Top 5) 2020(%)
    • Figure 10. BCG Matrix for key Companies
    • Figure 11. Sanofi S.A (France) Revenue, Net Income and Gross profit
    • Figure 12. Sanofi S.A (France) Revenue: by Geography 2020
    • Figure 13. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
    • Figure 14. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2020
    • Figure 15. Mylan Inc. (United States) Revenue, Net Income and Gross profit
    • Figure 16. Mylan Inc. (United States) Revenue: by Geography 2020
    • Figure 17. Apricus Biosciences Inc. (United States) Revenue, Net Income and Gross profit
    • Figure 18. Apricus Biosciences Inc. (United States) Revenue: by Geography 2020
    • Figure 19. Harbin Clinic (United States) Revenue, Net Income and Gross profit
    • Figure 20. Harbin Clinic (United States) Revenue: by Geography 2020
    • Figure 21. Pacira (Skyepharma) (United States) Revenue, Net Income and Gross profit
    • Figure 22. Pacira (Skyepharma) (United States) Revenue: by Geography 2020
    • Figure 23. Biomag Medical s.r.o. (Czech Republic) Revenue, Net Income and Gross profit
    • Figure 24. Biomag Medical s.r.o. (Czech Republic) Revenue: by Geography 2020
    • Figure 25. Bayer AG (Germany) Revenue, Net Income and Gross profit
    • Figure 26. Bayer AG (Germany) Revenue: by Geography 2020
    • Figure 27. Healthy Life Pharma Private Limited (India) Revenue, Net Income and Gross profit
    • Figure 28. Healthy Life Pharma Private Limited (India) Revenue: by Geography 2020
    • Figure 29. Duchefa Farma B.V (Netherlands) Revenue, Net Income and Gross profit
    • Figure 30. Duchefa Farma B.V (Netherlands) Revenue: by Geography 2020
    • Figure 31. Pfizer (United States) Revenue, Net Income and Gross profit
    • Figure 32. Pfizer (United States) Revenue: by Geography 2020
    • Figure 33. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
    • Figure 34. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2020
    • Figure 35. Apricus Biosciences, Inc. (United States) Revenue, Net Income and Gross profit
    • Figure 36. Apricus Biosciences, Inc. (United States) Revenue: by Geography 2020
    • Figure 37. Covis Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
    • Figure 38. Covis Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
    • Figure 39. Global Raynaudís Phenomenon Management: by Test USD Million (2021-2026)
    • Figure 40. Global Raynaudís Phenomenon Management: by Treatment Type USD Million (2021-2026)
    • Figure 41. Global Raynaudís Phenomenon Management: by End-Use USD Million (2021-2026)
    Some of the key companies/manufacturers profiled in the report
    • Sanofi S.A (France)
    • GlaxoSmithKline (United Kingdom)
    • Mylan Inc. (United States)
    • Apricus Biosciences Inc. (United States)
    • Harbin Clinic (United States)
    • Pacira (Skyepharma) (United States)
    • Biomag Medical s.r.o. (Czech Republic)
    • Bayer AG (Germany)
    • Healthy Life Pharma Private Limited (India)
    • Duchefa Farma B.V (Netherlands)
    • Pfizer (United States)
    • Teva Pharmaceutical Industries Ltd. (Israel)
    • Apricus Biosciences, Inc. (United States)
    • Covis Pharmaceuticals, Inc. (United States)
    Additional players considered in the study are as follows:
    Sandoz International GmbH (Germany) , Unichempharma (India)
    Select License Type
    Sample Report Enquiry Before Buy Request Discount

    Speak with Analyst

    Want to find out more about this report?

    Get Free Consultation